BioMarin Pharmaceutical (BMRN) Expected to Release Earnings on Monday

BioMarin Pharmaceutical (NASDAQ:BMRN) is anticipated to release its Q3 2026 results after the market closes on Monday, October 26th. Analysts expect BioMarin Pharmaceutical to post earnings of ($0.0886) per share and revenue of $1.02 billion for the quarter. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, October 26, 2026 at 4:30 PM ET.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. During the same period in the previous year, the business posted $1.44 EPS. The company’s revenue for the quarter was up 20.0% on a year-over-year basis. On average, analysts expect BioMarin Pharmaceutical to post $2.59 EPS for the current fiscal year and $5.31 EPS for the next fiscal year.

BioMarin Pharmaceutical Stock Down 1.2%

Shares of BMRN stock opened at $55.95 on Friday. BioMarin Pharmaceutical has a 12 month low of $49.26 and a 12 month high of $70.98. The firm has a market cap of $10.83 billion, a PE ratio of 151.22, a price-to-earnings-growth ratio of 0.46 and a beta of 0.22. The stock has a 50 day moving average of $61.70 and a 200-day moving average of $58.65. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56.

Wall Street Analysts Forecast Growth

BMRN has been the topic of several research analyst reports. Jefferies Financial Group raised their price objective on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $86.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 20th. Raymond James Financial upgraded shares of BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 target price for the company in a research note on Monday, October 12th. Canaccord Genuity Group increased their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, Citigroup increased their price target on shares of BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.60.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.